Przegląd Gastroenterologiczny

Prognostic value of TRIM24 expression in gastric cancer and various human solid tumours: a comprehensive cross-sectional, and meta-analysis study

Ali Beheshti Namdar 1
,
Pegah Bahram 2
,
Ladan Goshayeshi 1
,
Hassan Mehrad-Majd 3, 4
  1. Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  3. Cancer Molecular Pathology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
  4. Clinical Research Development Unit, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Gastroenterology Rev
DOI: https://doi.org/10.5114/pg.2026.161886
Data publikacji online: 2026/05/27
Plik artykułu
Prognostic value.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
  2. Akbarpour E, Sadjadi A, Derakhshan MH, et al. Gastric cancer in Iran: an overview of risk factors and preventive measures. Arch Iran Med 2021; 24: 556-67.
  3. Borji A, Bayat M, Shamsabadi F, et al. Epidemiology of gastrointestinal cancers (stomach, esophageal and colorectal) in Neyshabur city during 2006-2012. J Neyshabur Univ Med Sci 2016; 4: 37-44.
  4. Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018; 10: 239-48.
  5. Betts G, Valentine H, Pritchard S, et al. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virch Arch 2014; 464: 145-56.
  6. Chan AO. E-cadherin in gastric cancer. World J Gastroenterol 2006; 12: 199-203.
  7. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-9.
  8. Tabernero J, Hozak RR, Yoshino T, et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol 2018; 29: 602-9.
  9. Xu DZ, Geng QR, Tian Y, et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 2010; 10: 536.
  10. Li QF, Yao RY, Liu KW, et al. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 2010; 25: 846-52.
  11. Mohammadi M, Moradi A, Farhadi J, et al. Prognostic value of visfatin in various human malignancies: a systematic review and meta-analysis. Cytokine 2020; 127: 154964.
  12. Arjmand MH, Moradi A, Akbari A, Mehrad-Majd H. Clinical significance of circulating omentin levels in various malignant tumors: evidence from a systematic review and meta-analysis. Cytokine 2020; 125: 154869.
  13. Mehrad-Majd H, Ravanshad S, Moradi A, et al. Decreased expression of lncRNA loc285194 as an independent prognostic marker in cancer: a systematic review and meta-analysis. Pathol Res Pract 2019; 215: 152426.
  14. Mohammadi M, Mianabadi F, Mehrad-Majd H. Circulating visfatin levels and cancers risk: a systematic review and meta-analysis. 2019; 234: 5011-22.
  15. Mehrad-Majd H, Akhtari J, Haerian MS, Ravanshad Y. Clinicopathological and prognostic value of lncRNA PANDAR expression in solid tumors: evidence from a systematic review and meta-analysis. J Cell Physiol 2019; 234: 4206-16.
  16. Goshayeshi L, Afshar J, Mehrad-Majd H. Clinical significance of TRIM44 expression in patients with gastric cancer. Asian Pac J Cancer Prev 2022; 23: 1725-31.
  17. Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 2017; 42: 297-311.
  18. Jaworska AM, Wlodarczyk NA, Mackiewicz A, Czerwinska P. The role of TRIM family proteins in the regulation of cancer stem cell self-renewal. Stem Cells 2020; 38: 165-73.
  19. Wan T, Li X, Li Y. The role of TRIM family proteins in autophagy, pyroptosis, and diabetes mellitus. Cell Biol Int 2021; 45: 913-26.
  20. Groner AC, Cato L, de Tribolet-Hardy J, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 2016; 29: 846-58.
  21. Zhang LH, Yin AA, Cheng JX, et al. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. Oncogene 2015; 34: 600-10.
  22. Fang Z, Deng J, Zhang L, et al. TRIM24 promotes the aggression of gastric cancer via the Wnt/b-catenin signaling pathway. Oncol Letters 2017; 13: 1797-806.
  23. Tian H, Zhao H, Qu B, et al. TRIM24 promotes colorectal cancer cell progression via the Wnt/b-catenin signaling pathway activation. Am J Transl Res 2022; 14: 831-48.
  24. Jiang T, Mao H, Chen Q, et al. Trim24 prompts tumor progression via inducing EMT in renal cell carcinoma. Open Med 2020; 15: 1153-62.
  25. Zhou HE, Pan SS, Han H. TRIM24 aggravates the progression of ovarian cancer through negatively regulating FOXM1 level. Eur Rev Med Pharmacol Sci 2019; 23: 10647-56.
  26. Xie W, Zhang Y, Wang B, et al. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling. Cancer Med 2020; 9: 6367-76.
  27. Cui Z, Cao W, Li J, et al. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS One 2013; 8: e63887.
  28. Miao ZF, Wang ZN, Zhao TT, et al. TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance. Virch Arch 2015; 466: 525-32.
  29. Ma L, Yuan L, An J, et al. Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer. Tumour Biol 2016; 37: 14803-12.
  30. Lin L, Zhao W, Sun B, et al. Overexpression of TRIM24 is correlated with the progression of human cervical cancer. Am J Transl Res 2017; 9: 620-8.
  31. Wang FQ, Han Y, Yao W, Yu J. Prognostic relevance of tripartite motif containing 24 expression in colorectal cancer. Pathol Res Pract 2017; 213: 1271-5.
  32. Chambon M, Orsetti B, Berthe ML, et al. Prognostic significance of TRIM24/TIF-1a gene expression in breast cancer.
  33. Am J Pathol 2011; 178: 1461-9.
  34. Liu X, Huang Y, Yang D, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. PLoS One 2014; 9: e85462.
  35. Offermann A, Roth D, Hupe MC, et al. TRIM24 as an independent prognostic biomarker for prostate cancer. Urol Oncol 2019; 37: 576.e1-10.
  36. Zhang L, Chen H, Ding B, Jiang W. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer. J Ovarian Res 2022; 15: 19.
  37. Chi J, Yang Q, Xie XF, et al. Clinical significance and prognostic value of TRIM24 expression in esophageal squamous cell carcinoma. Aging 2016; 8: 2204-21.
  38. Jiang S, Minter LC, Stratton SA, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 2015; 62: 371-9.
  39. Farhadi J, Goshayeshi L, Motavalizadehkakhky A, et al. Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer. J Gastrointest Cancer 2022; 53: 179-86.
  40. Klapper L, Idel C, Kuppler P, et al. TRIM24 expression as an independent biomarker for prognosis and tumor recurrence in HNSCC. J Pers Med 2022; 12: 991.
  41. Wang H, Xue W, Jiang X. Overexpression of TRIM24 stimulates proliferation and glucose metabolism of head and neck squamous cell carcinoma. Biomed Res Int 2018; 2018: 6142843.
  42. Lv D, Li Y, Zhang W, et al. TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma. Nat Commun 2017; 8: 1454.
  43. Xue D, Zhang X, Zhang X, et al. Clinical significance and biological roles of TRIM24 in human bladder carcinoma. Tumour Biol 2015; 36: 6849-55.
  44. Li H, Sun L, Tang Z, et al. Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS One 2012; 7: e37657.
  45. Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010; 468: 927-32.
  46. Wang S, Zhao L, Yan H. Expression of CD44, TRIM24, TAGLN-2, ER and PR in breast invasive ductal carcinoma and their clinicopathologic significance. Chinese J Clin Exp Pathol 2017: 724-7.
  47. Khetchoumian K, Teletin M, Tisserand J, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 2007; 39: 1500-6.
  48. Bodnar L, Stanczak A, Cierniak S, et al. Wnt/b-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res 2014; 7: 16.
  49. Kim H, Yoo SB, Sun P, et al. Alteration of the E-cadherin/b-catenin complex is an independent poor prognostic factor in lung adenocarcinoma. Korean J Pathol 2013; 47: 44-51.
  50. Pang H, Lu H, Song H, et al. Prognostic values of osteopontin-c, E-cadherin and b-catenin in breast cancer. Cancer Epidemiol 2013; 37: 985-92.
  51. Elzagheid A, Buhmeida A, Korkeila E, et al. Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 2008; 14: 3866-71.
  52. Wang L, Heidt DG, Lee CJ, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 2009; 15: 207-19.
  53. He Y, Peng KW, Tang T, et al. Prognostic implications of tripartite motif containing 24 expression levels in patients with solid tumors: a systematic review and meta-analysis. Genet Testing Mol Biomarkers 2019; 23: 473-9.
  54. Xue Y, Ge W, Shi W, et al. Prognostic role of tripartite motif containing 24 in various human solid malignant neoplasms: an updated meta-analysis and systematic review. Medicine 2021; 100: e28383.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
without publication fees
Dostępne w
Indeksowane w
pubmed
Zintergrowane z
integrated with publons
plagiat pl
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications